Will MDR Delays Create Roadblocks For Companion Diagnostics Regulation?
Executive Summary
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
You may also be interested in...
European Commission Publishes Draft Rules In Bid To Reclassify Non-Medical Active Products
The European Commission has launched an initiative to ensure products without a medical purpose that fall under the Medical Device Regulation are appropriately classified by risk, and subject to the same pre- and post-market requirements as comparable medical devices.
Why EU Regulations Are Changing The Face Of Innovation And May Be Unsustainable
The EU must keep its medtech regulation under review as rapidly changing technology and external market factors may be challenging the operability of some aspects of the new medtech regulations, especially for less mature businesses and SMEs. Legal medtech expert, Shuna Mason, of CMS explains why.
No Quick Fix When It Comes To EU Medtech Notified Body Designations
Latest information from the European Commission suggest that future notified bodies designated under the MDR, and even the IVDR, may not be in a position to issue certificates until March 2023.